Association of grade ≥3 neutropenia (NP) with outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel

2018-10-01

Annals of Oncology , Volume 29 p. viii280- viii281

Additional Metadata
Persistent URL	doi.org/10.1093/annonc/mdy284.020, hdl.handle.net/1765/125537
Journal	Annals of Oncology
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Meisel, A., de Wit, R., Oudard, S., Sartor, O., Stenner-Liewen, F., Shun, Z. (Z.), … de Bono, J. (2018). Association of grade ≥3 neutropenia (NP) with outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel. Annals of Oncology, 29, viii280–viii281. doi:10.1093/annonc/mdy284.020

Publication